 Clinical Oncology News | New Antibody Promising for Relapsed Lymphoma Clinical Oncology News San Diego—In the first head-to-head comparison, obinutuzumab (GA101, Genentech) appeared to be more active than rituximab in relapsed CD20-positive indolent B-cell non-Hodgkin's lymphoma (NHL). Although only a Phase II study, the multinational, ... |
